1. Home
  2. GCTK vs ZVSA Comparison

GCTK vs ZVSA Comparison

Compare GCTK & ZVSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GCTK
  • ZVSA
  • Stock Information
  • Founded
  • GCTK 2001
  • ZVSA 2014
  • Country
  • GCTK United States
  • ZVSA United States
  • Employees
  • GCTK N/A
  • ZVSA N/A
  • Industry
  • GCTK Medical/Dental Instruments
  • ZVSA Biotechnology: Pharmaceutical Preparations
  • Sector
  • GCTK Health Care
  • ZVSA Health Care
  • Exchange
  • GCTK Nasdaq
  • ZVSA Nasdaq
  • Market Cap
  • GCTK 3.7M
  • ZVSA 3.0M
  • IPO Year
  • GCTK N/A
  • ZVSA N/A
  • Fundamental
  • Price
  • GCTK $5.60
  • ZVSA $0.57
  • Analyst Decision
  • GCTK
  • ZVSA
  • Analyst Count
  • GCTK 0
  • ZVSA 0
  • Target Price
  • GCTK N/A
  • ZVSA N/A
  • AVG Volume (30 Days)
  • GCTK 1.6M
  • ZVSA 11.7M
  • Earning Date
  • GCTK 08-12-2025
  • ZVSA 08-08-2025
  • Dividend Yield
  • GCTK N/A
  • ZVSA N/A
  • EPS Growth
  • GCTK N/A
  • ZVSA N/A
  • EPS
  • GCTK N/A
  • ZVSA N/A
  • Revenue
  • GCTK N/A
  • ZVSA N/A
  • Revenue This Year
  • GCTK N/A
  • ZVSA N/A
  • Revenue Next Year
  • GCTK N/A
  • ZVSA N/A
  • P/E Ratio
  • GCTK N/A
  • ZVSA N/A
  • Revenue Growth
  • GCTK N/A
  • ZVSA N/A
  • 52 Week Low
  • GCTK $5.16
  • ZVSA $0.47
  • 52 Week High
  • GCTK $3,756.00
  • ZVSA $5.30
  • Technical
  • Relative Strength Index (RSI)
  • GCTK 40.61
  • ZVSA 41.72
  • Support Level
  • GCTK $5.61
  • ZVSA $0.65
  • Resistance Level
  • GCTK $7.38
  • ZVSA $1.67
  • Average True Range (ATR)
  • GCTK 1.25
  • ZVSA 0.12
  • MACD
  • GCTK 0.04
  • ZVSA -0.01
  • Stochastic Oscillator
  • GCTK 4.40
  • ZVSA 0.52

About GCTK GlucoTrack Inc.

GlucoTrack Inc is a medical device company. It is focused on defining novel approaches that make diabetes management more accurate and convenient for daily living. The company has developed the GlucoTrack model that measures real-time blood glucose levels. The Company is developing an long-term implantable continuous blood glucose monitoring (CBGM) system, built on proven healthcare technologies. It is designed to meet the critical needs of insulin-dependent individuals or those at risk of hypoglycemia in the U.S.

About ZVSA ZyVersa Therapeutics Inc.

ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.

Share on Social Networks: